Caladrius Biosciences to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Thursday, February 25, 2...
February 18 2021 - 4:05PM
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the
“Company”), a clinical-stage biopharmaceutical company dedicated to
the development of cellular therapies designed to reverse disease,
today announced that the Company will report its financial results
for the three and twelve months ended December 31, 2020 on
Thursday, February 25, 2021 at 4:30 p.m. Eastern Time.
Live Conference Call and Webcast Details:
U.S. Toll-Free:
866-595-8403International:
706-758-9979Conference ID / Passcode:
7372695Webcast Link: Click here
Please dial-in at least 10 minutes before the conference call
starts.
For those unable to participate in the live conference call, an
audio replay will be available approximately two hours after the
call has concluded until March 4, 2021, by dialing 855-859-2056
(domestic) or 404-537-3406 (international) and referencing
conference ID / passcode: 7372695. A webcast recording of the call
will also be archived for 90 days under the Investors section of
the Company’s website at www.caladrius.com.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical-stage
biopharmaceutical company dedicated to the development of cellular
therapies designed to reverse disease. We are developing
first-in-class cell therapy products based on the finely tuned
mechanisms for self-repair that exist in the human body. Our
technology leverages and enables these mechanisms in the form of
specific cells, using formulations and modes of delivery unique to
each medical indication.
The Company’s current product candidates include: CLBS16, the
subject of both a recently completed positive Phase 2a study and a
newly initiated Phase 2b study in the U.S. for the treatment of
coronary microvascular dysfunction (“CMD”); HONEDRA® (CLBS12),
recipient of SAKIGAKE designation and eligible for early
conditional approval in Japan for the treatment of critical limb
ischemia (“CLI”) and Buerger’s Disease based on the results of an
ongoing clinical trial; CLBS201, designed to assess the safety and
efficacy of CD34+ cell therapy as a treatment for chronic kidney
disease (“CKD”) and OLOGO™ (CLBS14), a Regenerative Medicine
Advanced Therapy (“RMAT”) designated therapy for which the Company
is in discussion with the U.S. Food and Drug Administration (the
“FDA”) to finalize a Phase 3 protocol of reduced size and scope for
a confirmatory trial in subjects with no-option refractory
disabling angina (“NORDA”).For more information on the company,
please visit www.caladrius.com.
Contact:
Investors:Caladrius Biosciences, Inc.John MendittoVice
President, Investor Relations and Corporate CommunicationsPhone:
+1-908-842-0084Email: jmenditto@caladrius.com
Media:W2O GroupChristiana PascalePhone: +1-212-257-6722Email:
cpascale@w2ogroup.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Apr 2023 to Apr 2024